Pamisel Achieves 50.9 Billion KRW in Sales Last Year... 'All-Time High'

Net Income of 10.1 Billion Won... 92% Increase Compared to Last Year

[Asia Economy Reporter Park Hyungsoo] Pharmicell achieved its best-ever performance last year due to increased demand for nucleosides, raw materials for COVID-19 diagnostic kits and RNA therapeutics.

Pharmicell announced on the 8th that it recorded sales of 50.9 billion KRW and net profit of 10.1 billion KRW last year, up 35% and 92% respectively from the previous year. Operating profit increased by 13% to 8.2 billion KRW.

The improvement in performance was driven by increased sales in the Chemical Business Division. The Chemical Business Division achieved sales of 49.8 billion KRW, a 41% increase compared to the previous year.

By product, sales of nucleosides used as raw materials for mRNA vaccine purification and RNA therapeutics reached 17.5 billion KRW. mPEG, used as a delivery vehicle for protein drugs and mRNA vaccines, achieved sales of 6.6 billion KRW. Sales of advanced materials related to 5G also reached 11.8 billion KRW.

A Pharmicell official said, "With the commercialization of mRNA vaccines, interest in RNA therapeutics is growing," adding, "Pharmaceutical companies are also accelerating the development of RNA therapeutics." He continued, "Once therapeutics are commercialized, large orders for nucleosides will increase," and "When the second plant is completed by the end of June this year, production volume and sales of raw pharmaceutical materials will increase together."

He also added, "The bio business division expanded its pipeline last year to include allogeneic stem cell therapeutics," and "clinical research for commercialization is progressing rapidly."

This content was produced with the assistance of AI translation services.